Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Encephalitis | 2 | 2024 | 109 | 1.630 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 2 | 2024 | 30 | 1.050 |
Why?
|
| Myelitis | 1 | 2023 | 15 | 0.840 |
Why?
|
| Dexamethasone | 1 | 2024 | 271 | 0.840 |
Why?
|
| Neuromyelitis Optica | 1 | 2023 | 32 | 0.830 |
Why?
|
| Status Epilepticus | 1 | 2024 | 140 | 0.820 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 518 | 0.760 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 71 | 0.700 |
Why?
|
| Brain Diseases | 1 | 2023 | 298 | 0.700 |
Why?
|
| Autoantibodies | 3 | 2024 | 426 | 0.530 |
Why?
|
| Neurodevelopmental Disorders | 3 | 2023 | 492 | 0.410 |
Why?
|
| Syndrome | 2 | 2023 | 1116 | 0.350 |
Why?
|
| Ethanol | 3 | 2015 | 161 | 0.320 |
Why?
|
| Child | 11 | 2024 | 24260 | 0.300 |
Why?
|
| Corticosterone | 2 | 2015 | 59 | 0.240 |
Why?
|
| Glutamate Decarboxylase | 1 | 2024 | 36 | 0.230 |
Why?
|
| Injections, Spinal | 1 | 2024 | 118 | 0.230 |
Why?
|
| Hashimoto Disease | 1 | 2024 | 21 | 0.230 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 124 | 0.230 |
Why?
|
| Retrospective Studies | 6 | 2024 | 16068 | 0.220 |
Why?
|
| Rituximab | 1 | 2024 | 155 | 0.220 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 30 | 0.220 |
Why?
|
| Aquaporin 4 | 1 | 2023 | 15 | 0.220 |
Why?
|
| Spin Labels | 1 | 2023 | 39 | 0.210 |
Why?
|
| Oligodendroglia | 1 | 2023 | 84 | 0.210 |
Why?
|
| Racemases and Epimerases | 1 | 2022 | 10 | 0.200 |
Why?
|
| NADP | 1 | 2022 | 48 | 0.200 |
Why?
|
| NAD | 1 | 2022 | 48 | 0.200 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2023 | 148 | 0.200 |
Why?
|
| Down Syndrome | 1 | 2024 | 195 | 0.190 |
Why?
|
| Humans | 14 | 2024 | 123258 | 0.190 |
Why?
|
| Pyridostigmine Bromide | 1 | 2021 | 13 | 0.190 |
Why?
|
| Multiple Sclerosis | 1 | 2024 | 335 | 0.180 |
Why?
|
| Seizures | 2 | 2023 | 874 | 0.180 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 48 | 0.180 |
Why?
|
| Movement Disorders | 1 | 2023 | 221 | 0.180 |
Why?
|
| Metabolic Diseases | 1 | 2022 | 130 | 0.180 |
Why?
|
| Prednisone | 1 | 2021 | 274 | 0.170 |
Why?
|
| Intensive Care Units | 1 | 2024 | 482 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 768 | 0.170 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 92 | 0.170 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2024 | 470 | 0.170 |
Why?
|
| Electroencephalography | 1 | 2024 | 857 | 0.160 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2021 | 170 | 0.160 |
Why?
|
| Population Surveillance | 1 | 2021 | 383 | 0.150 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 377 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2021 | 378 | 0.150 |
Why?
|
| Age Factors | 2 | 2021 | 2811 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 372 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 644 | 0.140 |
Why?
|
| Phenotype | 2 | 2023 | 4226 | 0.140 |
Why?
|
| Female | 7 | 2024 | 65619 | 0.130 |
Why?
|
| Intellectual Disability | 1 | 2023 | 1047 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 357 | 0.130 |
Why?
|
| Adolescent | 6 | 2024 | 19133 | 0.130 |
Why?
|
| Receptors, AMPA | 1 | 2015 | 49 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 2052 | 0.120 |
Why?
|
| Male | 9 | 2024 | 60337 | 0.120 |
Why?
|
| Disease Progression | 1 | 2021 | 2030 | 0.120 |
Why?
|
| Pregnanolone | 1 | 2014 | 11 | 0.120 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2014 | 4 | 0.120 |
Why?
|
| Conditioning, Operant | 1 | 2014 | 17 | 0.120 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2014 | 13 | 0.110 |
Why?
|
| Alcohols | 1 | 2014 | 16 | 0.110 |
Why?
|
| Central Nervous System Depressants | 1 | 2014 | 23 | 0.110 |
Why?
|
| Ventral Tegmental Area | 1 | 2014 | 50 | 0.110 |
Why?
|
| Nucleus Accumbens | 1 | 2014 | 54 | 0.110 |
Why?
|
| Child, Preschool | 4 | 2024 | 13918 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2023 | 2586 | 0.110 |
Why?
|
| Stroke | 1 | 2021 | 958 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 337 | 0.100 |
Why?
|
| Infant | 3 | 2021 | 12376 | 0.090 |
Why?
|
| Brain | 1 | 2023 | 2966 | 0.090 |
Why?
|
| Adult | 2 | 2024 | 29100 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2021 | 12169 | 0.060 |
Why?
|
| Self Administration | 2 | 2015 | 43 | 0.060 |
Why?
|
| Rats, Long-Evans | 2 | 2015 | 103 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 114 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 581 | 0.050 |
Why?
|
| Muscle Hypotonia | 1 | 2023 | 185 | 0.050 |
Why?
|
| Gait | 1 | 2023 | 146 | 0.050 |
Why?
|
| Nervous System | 1 | 2021 | 128 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2023 | 702 | 0.040 |
Why?
|
| Rats | 2 | 2015 | 3665 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8114 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2024 | 824 | 0.030 |
Why?
|
| Xanthenes | 1 | 2015 | 7 | 0.030 |
Why?
|
| Animals | 4 | 2022 | 33842 | 0.030 |
Why?
|
| Discrimination Learning | 1 | 2015 | 23 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2015 | 39 | 0.030 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2014 | 6 | 0.030 |
Why?
|
| Phenylacetates | 1 | 2014 | 23 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2014 | 64 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2014 | 89 | 0.030 |
Why?
|
| Benzamides | 1 | 2014 | 105 | 0.030 |
Why?
|
| Glycine | 1 | 2014 | 169 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 360 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3549 | 0.030 |
Why?
|
| Amino Acids | 1 | 2015 | 663 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 5056 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2014 | 305 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 522 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 6222 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 8868 | 0.020 |
Why?
|
| United States | 1 | 2024 | 10652 | 0.020 |
Why?
|